Waystar Considers Sale Amid Software Sector Downturn

Waystar, a prominent healthcare software provider, is reportedly exploring strategic options, including a potential sale, according to sources familiar with the situation. The company, which has been publicly traded since 2024, is seeking to navigate a challenging market environment as its stock has seen a significant decline.

Investment Bank Evercore Advises on Potential Sale

Based in Lehi, Utah, and Louisville, Kentucky, Waystar has engaged investment bank Evercore to advise on the process. Sources indicate that discussions are in preliminary stages, and there is no certainty that a sale will proceed. The company's decision to explore a sale comes after its market value fell to approximately $4.8 billion, following a 24% drop in share price this year amid a broader software sector selloff.

Waystar has positioned itself as a technology-focused entity, offering software solutions to automate and manage administrative tasks in healthcare. This strategic positioning was intended to attract higher valuations typically associated with tech companies. Initially, investors responded positively, driving the share price from $20 to a peak of $45 in 2025. However, concerns over potential disruptions from advancements in artificial intelligence have since pressured the stock.

Background and Ownership

Formed in 2017 through the merger of Zirmed and Navicure, Waystar has become a key player in healthcare revenue management. Its major investors include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, which took the company public two years ago. EQT holds a 13% stake, making it the largest shareholder, followed by CPPIB at 10% and BlackRock Institutional Trust Company at 8%, according to data from LSEG.

Despite the current market challenges, an auction process could reveal whether investor interest in software companies is rebounding. Neither Waystar nor its major stakeholders have commented on the potential sale. Evercore, the advisory bank, also did not respond to requests for comment.

Market Dynamics and Investor Sentiment

The software sector has faced headwinds as investors reassess valuations amid technological shifts. Analysts at Morgan Stanley have highlighted concerns that emerging AI technologies could disrupt existing software models, adding pressure to companies like Waystar. The firm's strategic review may be an attempt to capitalize on its current market position before further volatility.

Waystar's exploration of a sale underscores the challenges and opportunities facing technology companies in the healthcare sector. As the industry evolves, firms must adapt to changing investor expectations and technological landscapes.